News
The FDA's approval was based on a study of 11,400 people age 12 and older that compared the new low-dose vaccine with Moderna ...
The U.S. Food and Drug Administration has approved a new lower-dose vaccine for active immunization against COVID-19 caused ...
The U.S. Food and Drug Administration has approved Moderna's next-generation COVID-19 vaccine for everyone aged 65 and above, ...
The FDA has approved Nuvaxovid to prevent COVID-19 in adults 65 years and older and high-risk individuals 12 through 64 years.
Moderna Inc. gained U.S. approval for a new COVID vaccine for a narrower group of people, in the latest sign that regulators ...
Moderna announced this weekend that the Food and Drug Administration approved its lower-dose Covid-19 vaccine for adults 65 ...
The FDA approved Moderna’s new Covid-19 vaccine late Friday, though it placed restrictions on its use that the company’s ...
2dOpinion
MedPage Today on MSNAn Uncertain Vaccines Market Keeps Getting DicierUnpredictable and politically driven regulatory approaches cultivate an environment of enormous uncertainty for vaccine ...
The FDA’s approval was based on a study of 11,400 people ages 12 and older that compared the new low-dose vaccine with ...
Jefferies analysts said the approval was largely expected and an “incremental positive” for Moderna amid questions about the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results